| Cite this article: |
| LI Mengjun,LIU Bo,WANG Xiaobo,LI Yan,XIONG Shan,MOU Yanling,XIE Weilin.Stability and metabolites analysis of a novel diaryl derivative 04022a for melanoma treatment in different species of liver microsomes[J].Journal Of Pharmaceutical Research,2023,42(7):433-439[Click to copy] |
|
| 摘要: |
| 目的 采用SD大鼠、人、比格犬的肝微粒体酶,考察新型二芳基衍生物04022a在3个种属肝微粒体中的代谢稳定性,比较代谢的种属差异,并对产生的代谢产物进行筛选与结构表征。方法 将04022a溶解在由NADPH启动的肝微粒体孵育体系中,孵育0 、15 、30 、60 、90 、120 min后,加入等体积的冰甲醇终止反应。采用高效液相色谱法测定04022a的质量浓度,计算各个时间点的剩余药物百分比、体外半衰期(t1/2)和固有清除率(CLint)。采用超高效液相色谱串联飞行时间质谱法对04022a在肝微粒体中的代谢产物进行检测与分析。结果 孵育120 min时,04022a在大鼠、人、比格犬肝微粒体中的剩余药物百分比分别为88.30%、82.15%、98.63%。t1/2分别为770、364、3 465 min,CLint分别为0.001 8、0.003 8、0.000 4 mL•(min•mg)-1。初步判断04022a在3个种属共有5个体外代谢产物。结论 04022a在各种肝微粒体中的代谢稳定性良好,主要代谢转化途径包括脱烷基化、羟基化、脱氢。 |
| 关键词: 二芳基衍生物04022a 肝微粒体 代谢稳定性 代谢产物 黑色素瘤 |
| DOI:10.13506/j.cnki.jpr.2023.07.001 |
| 基金项目:山东第一医科大学学术提升计划(No.2019LJ003);国家自然科学基金(No.81903473) |
|
Publication Date:July 25, 2023
|
|
| Stability and metabolites analysis of a novel diaryl derivative 04022a for melanoma treatment in different species of liver microsomes |
| LI Mengjun,LIU Bo,WANG Xiaobo,LI Yan,XIONG Shan,MOU Yanling,XIE Weilin |
| (School of Pharmacy and Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, NHC Key Laboratory of biotechnology drugs (Shandong Academy of Medical Sciences) , Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan 250117, China) |
| Abstract: |
| Objective To investigate the metabolic stability of the novel diaryl derivative 04022a in liver microsomes of three species using liver microsomal enzymes from SD rats, humans, and beagles, compare the differences in metabolism among species, and screen and characterize the metabolites produced. Methods 04022a was dissolved in a liver microsome incubation system initiated by NADPH. After incubation for 0, 15, 30, 60, 90 and 120 min, the reaction was terminated by adding the same volume of ice methanol. The mass concentration of 04022a was determined by high performance liquid chromatography. The percentage of remaining drug, in vitro half-life (t1/2) and intrinsic clearance (CLint) were calculated at each time point. The metabolites of 04022a in liver microsomes were detected and analyzed by ultra performance liquid chromatography tandem time-of-flight mass spectrometry. Results After incubation for 120 min, the remaining drug percentages of 04022a in rat, human, and beagle liver microsomes were 88.30%, 82.15% and 98.63%, respectively. t1/2 was 770, 364 and 3 465 min and CLint was 0.001 8, 0.0038 and 0.000 4 mL•(min•mg)-1, respectively. It was preliminarily determined that 04022a had five extraneous metabolites in three species. Conclusion 04022a has good metabolic stability in various liver microsomes. The main metabolic transformation pathways include dealkylation, hydroxylation, dehydrogenation. |
| Key words: 04022a Liver microsomes Metabolic stability Metabolites |